Pneumococcal polysaccharide vaccines do not protect the elderly from pneumococcal infections

Netherlands Journal of Medicine

Volumn 62, Issue 2, 2004, Pages 33-35

  Lipsky, Benjamin A ^a   Hirschmann, J V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; STREPTOCOCCUS ANTIGEN;

AGED; BACTEREMIA; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EDITORIAL; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; INCIDENCE; INDUSTRIALIZATION; INFECTION PREVENTION; INFECTION RISK; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PREVENTIVE HEALTH SERVICE; QUALITY OF LIFE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VALIDATION PROCESS;

AGED; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY OF HEALTH CARE;

EID: 2442479715     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med 1994;154:373-7.
2. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003:CD000422.
3. Simberkoff MS. Recently Published Controlled Trials of Pneumococcal Vaccine Efficacy in Adults. Curr Infect Dis Rep 1999;1:47-8.
4. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399-403.
5. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17:2493-500.
6. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-90.
7. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318-27.
8. Hirschmann JV, Lipsky BA. Pneumococcal vaccine in the United States. A critical analysis. JAMA 1981;246:1428-32.
9. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
10. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999;45:2381-93.
11. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000;1:1.
12. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001;19:4780-90.
13. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002;20:2166-73.
14. Puig-Barbera J, Belenguer Varea A, Goterris Pinto M, Brines Benlliure MJ. [Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis]. Aten Primaria 2002;30:269-83.
15. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003;3:71-8.
16. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747-55.
17. Hirschmann JV. Pneumococcal vaccination in older adults. N Engl J Med 2003;349:712-4.
18. Rubins JB, Janoff EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging 2001;18:305-11.
19. Edwards KM, Griffin MR. Great expectations for a new vaccine. N Engl J Med 2003;349:1312-4.
20. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138:960-8.
21. Gardner P. A need to update and revise the pneumococcal vaccine recommendations for adults. Ann Intern Med 2003;138:999-1000.
22. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46:1-24.
23. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
24. Simberkoff MS. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness. Semin Respir Infect 1993;8:294-9.
25. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986;104:79-86.
26. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.
27. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000;31:444-50.
28. Jefferson T, Demicheli V. Polysaccharide pneumococcal vaccines. BMJ 2002;325:292-3.